Evidence map›Paper›PMID 27793332›Full record

ReviewBiological psychiatry2017

Enhancing the Informativeness and Replicability of Imaging Genomics Studies.

Cameron S Carter, Carrie E Bearden, Edward T Bullmore, Daniel H Geschwind, David C Glahn, Raquel E Gur, Andreas Meyer-Lindenberg, Daniel R Weinberger

Abstract readReview
In one paragraph

Review in Biological psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Imaging genetics paradigms in depression research: Systematic review and meta-analysis.Progress in neuro-psychopharmacology & biological psychiatry · 2018
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Open Science Practices in Psychiatric Genetics: A Primer.Biological psychiatry global open science · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021
    Review
  11. Deep Learning with Neuroimaging and Genomics in Alzheimer's Disease.International journal of molecular sciences · 2021
    Review
  12. Healthy individualsWorld journal of clinical cases · 2021
    Article
  13. Article
  14. Article
  15. Neuroimaging in Schizophrenia.Neuroimaging clinics of North America · 2020
    Review
  16. Article
  17. The Translational Potential of Neuroimaging Genomic Analyses To Diagnosis And Treatment In The Mental Disorders.Proceedings of the IEEE. Institute of Electrical and Electronics Engineers · 2019
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cameron S CarterUniversity of California at Davis, Sacramento. Electronic address: cameron.carter@ucdmc.ucdavis.edu.
Carrie E BeardenUniversity of California at Los Angeles, Los Angeles, California.
Edward T BullmoreCambridge University, Cambridge, United Kingdom.
Daniel H GeschwindYale University, New Haven, Connecticut.
David C GlahnUniversity of California at Los Angeles, Los Angeles, California.
Raquel E GurUniversity of Pennsylvania, Philadelphia, Pennsylvania.
Andreas Meyer-LindenbergUniversity of Heidelberg Central Institute of Mental Health, Mannheim, Germany.
Daniel R WeinbergerLieber Institute for Brain Development, Baltimore, Maryland.

Funding

PATHOPHYSIOLOGY OF COGNITIVE DISABILITY IN SCHIZOPHRENIAR01MH059883 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARTER, CAMERON S. · 2000 to 2017
$6.1M
NIMH NIH HHS R01 MH059883
6 · The paper itself

Abstract

Imaging genomics is a new field of investigation that seeks to gain insights into the impact of human genetic variation on the structure, chemistry, and function of neural systems in health and disease. Because publications in this field have increased over the past decade, increasing concerns have been raised about false-positive results entering the literature. Here, we provide an overview of the field of imaging genomic and genetic approaches and discuss factors related to research design and analysis that can enhance the informativeness and replicability of these studies. We conclude that imaging genetic studies can provide important insights into the role of human genetic variation on neural systems and circuits, both in the context of normal quantitative variation and in relation to neuropsychiatric disease. We also argue that demonstrating genetic association to imaging-derived traits is subject to the same constraints as any other genetic study, including stringent type I error control. Adequately powered studies are necessary; however, there are currently limited data available to allow precise estimates of effect sizes for candidate gene studies. Independent replication is necessary before a result can be considered definitive, and for studies with small sample sizes it is necessary before publication. Increased transparency of methods and enhanced data sharing will further enhance replicability.

Indexed as

GenomicsNeuroimagingBiomedical ResearchHumansMental DisordersPhenotypeReproducibility of ResultsClinical confoundsImaging genomicsMultiple comparisonsReplicationSample sizeStatistical power

Identifiers

PMID27793332
PMCPMC5318285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.